Jay Clemens
The Centers for Innovation in Advanced Development and Manufacturing has received an 18-month, $10.49 million task order from the Department of Health and Human Services to help the agency develop a second-generation anthrax vaccine.
CIADM is located at Texas A&M University in College Station will support development of Altimmune‘s NasoShield anthrax vaccine candidate that is meant to be delivered via nasal spray, HHS said Tuesday.
Altimmune will move its NasoShield manufacturing process and materials to the CIADM and Texas A&M will provide materials for clinical testing of the vaccine.
“To help combat the health impacts of an anthrax attack, [Biomedical Advanced Research and Development Authority] partnered with several biotechnology firms in accelerating development of promising next-generation treatments against anthrax infection,†said Richard Hatchett, acting BARDA director.
HHS noted the vaccine will employ the Adenovirus 5 viral vectored delivery technology designed to combine genetic material into a non-infectious virus in order to produce an immune response against anthrax.
